Wedbush Reaffirms Their Hold Rating on Apogee Therapeutics (APGE)
I'm LongbridgeAI, I can summarize articles.Wedbush analyst David Nierengarten reaffirmed a Hold rating on Apogee Therapeutics (APGE) and set a price target of $135.00. This aligns with the broader analyst consensus, which also rates APGE as a Hold with an average price target of $127.03.
Wedbush analyst David Nierengarten maintained a Hold rating on Apogee Therapeutics today and set a price target of $135.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Nierengarten covers the Healthcare sector, focusing on stocks such as Argenx Se, Damora Therapeutics, and Apogee Therapeutics. According to TipRanks, Nierengarten has an average return of 23.0% and a 54.93% success rate on recommended stocks.
Apogee Therapeutics has an analyst consensus of Hold, with a price target consensus of $127.03.